Cargando…
Podoplanin: An emerging cancer biomarker and therapeutic target
Podoplanin (PDPN) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition, migratio...
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980289/ https://www.ncbi.nlm.nih.gov/pubmed/29575529 http://dx.doi.org/10.1111/cas.13580 |
| _version_ | 1783327861326741504 |
|---|---|
| author | Krishnan, Harini Rayes, Julie Miyashita, Tomoyuki Ishii, Genichiro Retzbach, Edward P. Sheehan, Stephanie A. Takemoto, Ai Chang, Yao‐Wen Yoneda, Kazue Asai, Jun Jensen, Lasse Chalise, Lushun Natsume, Atsushi Goldberg, Gary S. |
| author_facet | Krishnan, Harini Rayes, Julie Miyashita, Tomoyuki Ishii, Genichiro Retzbach, Edward P. Sheehan, Stephanie A. Takemoto, Ai Chang, Yao‐Wen Yoneda, Kazue Asai, Jun Jensen, Lasse Chalise, Lushun Natsume, Atsushi Goldberg, Gary S. |
| author_sort | Krishnan, Harini |
| collection | PubMed |
| description | Podoplanin (PDPN) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition, migration, invasion, metastasis and inflammation. Antibodies, CAR‐T cells, biologics and synthetic compounds that target PDPN can inhibit cancer progression and septic inflammation in preclinical models. This review describes recent advances in how PDPN may be used as a biomarker and therapeutic target for many types of cancer, including glioma, squamous cell carcinoma, mesothelioma and melanoma. |
| format | Online Article Text |
| id | pubmed-5980289 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-59802892018-06-06 Podoplanin: An emerging cancer biomarker and therapeutic target Krishnan, Harini Rayes, Julie Miyashita, Tomoyuki Ishii, Genichiro Retzbach, Edward P. Sheehan, Stephanie A. Takemoto, Ai Chang, Yao‐Wen Yoneda, Kazue Asai, Jun Jensen, Lasse Chalise, Lushun Natsume, Atsushi Goldberg, Gary S. Cancer Sci Review Articles Podoplanin (PDPN) is a transmembrane receptor glycoprotein that is upregulated on transformed cells, cancer associated fibroblasts and inflammatory macrophages that contribute to cancer progression. In particular, PDPN increases tumor cell clonal capacity, epithelial mesenchymal transition, migration, invasion, metastasis and inflammation. Antibodies, CAR‐T cells, biologics and synthetic compounds that target PDPN can inhibit cancer progression and septic inflammation in preclinical models. This review describes recent advances in how PDPN may be used as a biomarker and therapeutic target for many types of cancer, including glioma, squamous cell carcinoma, mesothelioma and melanoma. John Wiley and Sons Inc. 2018-05 /pmc/articles/PMC5980289/ /pubmed/29575529 http://dx.doi.org/10.1111/cas.13580 Text en © 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| spellingShingle | Review Articles Krishnan, Harini Rayes, Julie Miyashita, Tomoyuki Ishii, Genichiro Retzbach, Edward P. Sheehan, Stephanie A. Takemoto, Ai Chang, Yao‐Wen Yoneda, Kazue Asai, Jun Jensen, Lasse Chalise, Lushun Natsume, Atsushi Goldberg, Gary S. Podoplanin: An emerging cancer biomarker and therapeutic target |
| title | Podoplanin: An emerging cancer biomarker and therapeutic target |
| title_full | Podoplanin: An emerging cancer biomarker and therapeutic target |
| title_fullStr | Podoplanin: An emerging cancer biomarker and therapeutic target |
| title_full_unstemmed | Podoplanin: An emerging cancer biomarker and therapeutic target |
| title_short | Podoplanin: An emerging cancer biomarker and therapeutic target |
| title_sort | podoplanin: an emerging cancer biomarker and therapeutic target |
| topic | Review Articles |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980289/ https://www.ncbi.nlm.nih.gov/pubmed/29575529 http://dx.doi.org/10.1111/cas.13580 |
| work_keys_str_mv | AT krishnanharini podoplaninanemergingcancerbiomarkerandtherapeutictarget AT rayesjulie podoplaninanemergingcancerbiomarkerandtherapeutictarget AT miyashitatomoyuki podoplaninanemergingcancerbiomarkerandtherapeutictarget AT ishiigenichiro podoplaninanemergingcancerbiomarkerandtherapeutictarget AT retzbachedwardp podoplaninanemergingcancerbiomarkerandtherapeutictarget AT sheehanstephaniea podoplaninanemergingcancerbiomarkerandtherapeutictarget AT takemotoai podoplaninanemergingcancerbiomarkerandtherapeutictarget AT changyaowen podoplaninanemergingcancerbiomarkerandtherapeutictarget AT yonedakazue podoplaninanemergingcancerbiomarkerandtherapeutictarget AT asaijun podoplaninanemergingcancerbiomarkerandtherapeutictarget AT jensenlasse podoplaninanemergingcancerbiomarkerandtherapeutictarget AT chaliselushun podoplaninanemergingcancerbiomarkerandtherapeutictarget AT natsumeatsushi podoplaninanemergingcancerbiomarkerandtherapeutictarget AT goldberggarys podoplaninanemergingcancerbiomarkerandtherapeutictarget |